Interleukin-10 production in response to amyloid-beta differs between slow and fast decliners in patients with Alzheimer's disease
Manuscript Number:
14-2832R1
Author(s):
Giorgio Annoni, Beatrice Arosio, Delphine Asselineau, Jean-Louis Beaudeux, Joel Belmin, Khadija Benlhassan, Anne Bornand, Dorothy H. Bray, Martina Casati, Mohamed Doulazmi, Evelyn Ferri, Cristina Gussago, Daniela Mari, Jean Mariani, Paolo Mazzola, Sylvie Pariel, Francois Piette, Enzo Tedone
Disclosures
Giorgio Annoni
Nothing to Disclose
Beatrice Arosio
Nothing to Disclose
Delphine Asselineau
Sponsors:
I was employed as PhD student by ImmunoClin. My PhD has been supported by CIFRE grant and supervised by Dr. Dorothy Bray and Pr. Jean Mariani (UMR 7102, NPA Equipe Développement et Vieillissement du Système Nerveux (DVSN) UPMC, 9, quai St Bernard, 75005 PARIS)
Grants
Agency:
ANRT (CIFRE n° 2010/0793)
Dates:
2010 to 2012
Jean-Louis Beaudeux
Nothing to Disclose
Joel Belmin
Lecture Fees:
Herpes zoster Sanofi, pasteur, MSD
Osteoporosis : Amgen
News in geriatric medicine : Novartis
Khadija Benlhassan
Consulting Fees:
I am director and Chief Scientific Officer of ImmunoClin Corporation and ImmunoClin Limited is a wholly-owned subsidiary of ImmunoClin Corporation.
Equity:
Yes I own 100 000 preferred shares series A of ImmunoClin Corporation.
Anne Bornand
Nothing to Disclose
Dorothy H. Bray
Equity:
ImmunoClin LTD is a 100% owned subsidiary of IMMUNOCLIN CORPORATION (IMCL), I own 12,370,000 shares of common and class A shares and stock options.
Patents/Royalties
ImmunoClin holds multiple patents including paten
Martina Casati
Nothing to Disclose
Mohamed Doulazmi
Nothing to Disclose
Evelyn Ferri
Nothing to Disclose
Cristina Gussago
Nothing to Disclose
Daniela Mari
Nothing to Disclose
Jean Mariani
Equity:
Yes I own 10 000 common shares of ImmunoClin Corporation. ImmunoClin Limited, a wholly-owned subsidiary of ImmunoClin Corporation”